Trial Profile
Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Milciclib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Sponsors Nerviano Medical Sciences; Tiziana Life Sciences
- 22 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Jun 2018 Primary endpoint (Progression-free survival rate at 3 months) has been met, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results assessing efficacy from 2 phase II studies (NCT01011439 and NCT01301391) presented at the 54th Annual Meeting of the American Society of Clinical Oncology